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Abstract: The complexity of treating severe sepsis and septic shock has been elucidated in 
myriad studies, particularly in the past 10 years. The development of clinical guidelines, insight 
into the effect of bundle elements, and results of clinical trials have brought to light further 
opportunities and questions in the approach to pharmaceutical interventions for the global 
challenge to save lives and reduce healthcare costs. Therapeutic interventions including fluid 
resuscitation, hemodynamic monitoring, glycemic control, corticosteroids, and antimicrobial 
therapy and stewardship inform outcomes. Research on biomarkers, use of mesenchymal stem 
cells, blood purification, immunoglobulins, and antioxidative treatments apropos the immune 
response may soon yield viable therapies.
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Introduction
Severe sepsis is a complex syndrome that has been estimated to affect more than 
750,000 people annually in the US alone. Epidemiology studies indicate that the 
number of people diagnosed with severe sepsis and septic shock is increasing year 
by year, eclipsing the incidence of stroke, cancer, and myocardial infarction as well 
as contributing enormously to health care costs.1 An aging population admitted to the 
hospitals with many comorbid conditions contributes to these increases. Simultane-
ously, outcomes have been improving. A retrospective, observational study including 
more than 100,000 patients with severe sepsis in Australia and New Zealand found 
that hospital mortality decreased steadily throughout the last decade.2 Interestingly, the 
authors found the same improvement occurred in nonseptic patients, but such patients 
had lower rates of discharge to home and higher rates of discharge to rehabilitation. 
In a similar time frame, Levy et al3 analyzed the association between compliance with 
the Surviving Sepsis Campaign (SSC) performance bundles and mortality measured 
in 29,470 subjects over 7.5 years and found that increased compliance with sepsis 
performance bundles was associated with a 25% relative risk reduction in mortality 
rate. Moreover, every 10% increase in compliance was associated with a significant 
decrease in the odds ratio (OR) for hospital mortality. The dissemination of awareness 
has contributed to increased successful initiatives of early recognition and imple-
mentation of protocols for better patient care. In addition, the hospital community is 
increasing the development of multidisciplinary approaches and shared protocols with 
simple interventions that might dramatically change the management of the patients.4 
Unfortunately, over the last few years, many studies have been conducted in order 
to decrease the mortality rate associated with sepsis, but the pharmaceutical research 
community is not getting any substantial new messages regarding drug design, devel-
opment, and therapy with a unanimous rate of failure.5,6 The improved communication 
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among intensive care practitioners, emergency department 
personnel, and wards staff regarding best practices for early 
recognition and management of patients with severe sepsis 
has no doubt contributed to better patient care.
Epidemiology
The global epidemiologic data regarding outcomes for 
patients in intensive care units (ICUs) are scarce, but are 
important in understanding the worldwide burden of critical 
illness. The Intensive Care Over Nations (ICON) audit had a 
total of 730 participating centers in 84 countries comprising 
more than 10,000 patients.7 One-third of the patients had 
severe sepsis on admission or during the ICU stay; and while 
the general ICU mortality rate was 16.2%, the number almost 
doubled (25.8%) in patients with sepsis. The same trend was 
also seen when hospital mortality was analyzed. Hospitals 
have recognized the burden of sepsis and are currently at 
a landmark point for implementing strategic policies that 
address this within their facilities. The acknowledgment of 
the increasing sepsis rate has helped health authorities facili-
tate the acquisition of resources that foster needed policy and 
management pathways in designated areas.
It is important to note that despite the increasing number 
of severe sepsis patients, inconsistent coding obscures exact 
numbers. As Rhee et al8 have described, the “suspected 
infection” code is problematic. They report a dichotomous 
sustained decrease in hospitalizations for the infections that 
most commonly cause sepsis (pneumonia, urinary tract 
infections, intra-abdominal infections, and bacteremia). 
The implementation of policy mandates and surveillance 
methods might help clinicians and authorities better deter-
mine the “true” incidence of sepsis in the health care system. 
Doing so might balance the overuse of advanced diagnostic 
tools with judicious management processes and contain the 
use of broad-spectrum antibiotics. While antibiotic steward-
ship programs should be implemented, the burden of sepsis 
and the high associated mortality should determine a success-
ful balance in the near future. Similar to other well-known 
diseases, prompt recognition has resulted in improved patient 
outcomes. Acute myocardial infarction (“door to balloon”), 
stroke (“time lost is brain lost”), and trauma (“golden hour”) 
are good examples of key messages about early recognition 
that can have a huge impact.
Implementation of guidelines 
and bundles
Following the publication of the Surviving Sepsis Campaign 
Guidelines in 2004,9 individual elements of care that were 
shown to produce better outcomes when applied together 
were grouped into “bundles of care”. Similarly, in patients 
with acute myocardial infarction, the successful event of 
opening an occluded coronary artery is the key intervention 
in the treatment process. In severe sepsis and septic shock, 
many interventions need to be completed at the same time 
using a multidisciplinary approach. The SSC grouped inter-
ventions into two bundles of care: the resuscitation bundle 
and the management bundle, which were to be achieved 
over the first 6 and 24 hours from recognition of severe 
sepsis, respectively. Application of this multidisciplinary, 
global approach resulted in a reduction of hospital mortality 
directly related to the implementation of the care bundles.10 
In a multicenter, prospective study with a large cohort of 
severely septic patients in which an educational program 
based on SSC guidelines and bundles was implemented, 
Ferrer et al11 demonstrated improvement in the application 
of individual process-of-care bundle elements and reduced 
mortality in patients with severe sepsis and septic shock. 
Interestingly, a further study that aimed to evaluate the 
cost-effectiveness of the SSC protocol after the implemen-
tation of an educational program found that mean costs per 
patient were higher in the SSC protocol care cohort, largely 
as a result of increased length of stay; however, mean life 
years gained were higher in the SSC protocol care cohort, 
0.54 years (95% CI 0.02–1.05 years), demonstrating that the 
SSC protocol seems to be a cost-effective option.12
More recently, Castellanos-Ortega et al13 performed a 
quasi-experimental study with a historical comparison group 
to determine the contribution of the various elements of the 
bundles to the outcome and found that the benefits depended 
on the number of interventions accomplished within the 
time limits. The 6-hour resuscitation bundle showed greater 
compliance and effectiveness than the 24-hour manage-
ment bundle. This also supports the theory that the most 
important parts of the process of care are related to early 
intervention.
Guidelines and bundles updates
In 2012, SSC updated the guidelines based on new evidence 
since the first revision of 2008.14,15 Several recommendations 
were updated (Table 1). However, several elements remain 
controversial.
The ProCESS trial randomized and included 1,341 patients 
with early septic shock and compared three management 
strategies: Protocolized Early Goal-Directed Therapy 
(EGDT), protocolized standard care, and usual care.16 The 
main conclusion is that protocol-based EGDT using central 
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venous catheterization and oxygen-saturation monitoring 
does not lead to better outcomes for septic patients when 
compared with management without a protocol. While this 
study could not show the beneficial effect of EGDT, one point 
was especially relevant: Early detection with timely adminis-
tration of antibiotics and fluids was the single most important 
factor in reducing mortality and morbidity from sepsis. In 
addition, when comparing the different study groups, no ben-




 or central venous pressure 
(CVP) measurements and might allow for the refinement of 
EGDT by defining fluid administration boundaries to avoid 
the complications of renal failure and pulmonary dysfunc-
tion. What the study could not say was that hemodynamic 
monitoring should be eliminated in relation to care of patients 
with severe sepsis. Importantly, the true mortality figures in 
this study were around 28% at 60 days and around 32% at 
90 days due to the way the mortality data were censored at 
hospital discharge. The sample size had to be recalculated 
in the first interim analysis based on apparent lower mor-
tality rates and the fact that the fluid challenge defined in 
the protocol as 20 mL/kg over 30 minutes was modified to 
1,000 mL of fluids over 30 minutes, which may have led to 
the inclusion of less sick patients (Figure 1).
The results from the Australasian Resuscitation In 
Sepsis Evaluation (ARISE) Randomised Controlled Trial 
also showed that in critically ill patients presenting to the 
emergency department with early septic shock, EGDT did 
not reduce all-cause mortality at 90 days.17 In light of the 
evidence from the ProCESS and ARISE trials and pend-
ing the results of the Protocolized Management in Sepsis 
(ProMISe) Trial, the SSC guidelines committee will review 
the evidence and assess whether the guidelines need to be 
updated.18 The SSC bundles will also be reviewed and revised 
as needed on the basis of the recommendations.
Current antibiotic strategies 
for severe sepsis and septic shock
The use of early and appropriate antibiotic therapy is cru-
cial to improved survival rates in severe sepsis and septic 
shock. Early antimicrobial therapy along with other sup-
portive resuscitation goals should be achieved to avoid the 
further development of cellular dysfunction, tissue injury, 
and overwhelming inflammatory response. This theory 
was launched 100 years ago with Paul Ehrlich’s paradigm: 
Table 1 SSC 2013 updates
• Antibiotics within 1 hour (1C).
• CvP 8–12 mmHg (1C) and MAP 65 mmHg (Grade 1C).
• No corticosteroids in the absence of refractory shock (Grade 1D).
• Crystalloids as first choice (1B) and against hydroxyethyl starches (1B).
•  NE first choice (1B) with E added or substituted if not adequate BP 
(Grade 2B).
•  Phenylephrine not recommended except arrhythmias, high CO and BP 
low or rescue (1C).
• Dobutamine if myocardial dysfunction (1C) not for supranormal (1B).
•  Protocolized approach blood glucose 180 mg/dL and target an upper 
blood glucose 180 mg/dL (1A).
• Maintain inspiratory plateau pressure 30 cm H2O (1B).
Abbreviations: SSC, Surviving Sepsis Campaign; CvP, central venous pressure; MAP, 
mean arterial pressure Ne, Norepinephrine; BP, blood pressure; CO, cardiac output. 
Figure 1 Fluid administration between 0 and 6 hours.
Abbreviations: ProCeSS, Protocolized Care for early Septic Shock; eGDT, early Goal-Directed Therapy.





“Frapper fort et frapper vite” or “Hit hard and hit fast”. 
Kumar et al19 analyzed a retrospective cohort of 2,731 
adult patients with septic shock and found that effective 
antimicrobial administration within the first hour of docu-
mented hypotension was associated with increased survival 
to hospital discharge.20 Despite a progressive increase in 
mortality rate with increasing delays, only 50% of septic 
shock patients received effective antimicrobial therapy 
within 6 hours of documented hypotension. Several articles 
have also reported similar results, which make the common 
delay in the administration of antibiotics puzzling (Table 2). 
Ferrer et al20 conducted a retrospective analysis of 17,990 
patients from 28,150 patients with severe sepsis and septic 
shock collected prospectively for the SSC database from 165 
multinational ICUs in Europe, USA, and South America. 
The results demonstrate that a delay in first antibiotic admin-
istration was associated with increased in-hospital mortality, 
with a linear increase in the mortality for each hour’s delay 
in antibiotic administration. Moreover, the adjusted hospital 
mortality ORs steadily increased from 1.00 to 1.52 as time 
to antibiotic administration increased from 0 to 6 hours, 
where 0–1 hour is the referent group. The probability of 
mortality increased from 24.6% to 33.1%. It is important to 
determine that time of severe sepsis recognition, rather than 
onset, is used as “time zero”, or “when the clock starts”, for 
determining elapsed time to antibiotics.
Antibiotic stewardship in severe 
sepsis and septic shock: combination 
vs de-escalation
Recent studies show that some antibiotic strategies can 
improve survival in patients with severe sepsis and septic 
shock. Díaz-Martín et al21 found that in patients who received 
antimicrobials within the first 6 hours of diagnosis, combina-
tion antimicrobial agents with different mechanisms of action – 
termed “different-class combination therapy” (DCCT) – may 
be useful in a subset of critically ill patients. Particularly in 
those with septic shock in more than 1,000 patients with 
severe sepsis, the mortality rate was significantly lower in 
patients administered DCCTs than in those who were admin-
istered monotherapy and any other combination therapy 
possibilities (non-DCCT). On the other hand, Brunkhorst 
et al22 could not find any benefit from treatment with 
combined meropenem and moxifloxacin compared with 
meropenem alone in mortality or organ failure. Antibiotic 
stewardship strategies are necessary to counterbalance the 
administration of appropriate antibiotic treatment in a timely 
manner with the threat of generating resistance.
De-escalation of antimicrobials in patients with severe 
sepsis is one approach. De-escalation, defined as discon-
tinuation of an antimicrobial agent or change of antibiotic 
to one with a narrower spectrum once culture results were 
available, was analyzed by Garnacho-Montero et al.23 The 
authors carried out a prospective observational study of 
patients with severe sepsis or septic shock and found that 
de-escalation was applied to one-third of the patients. 
Not only the multivariate analysis, but also the propensity-
score adjusted logistic regression models confirmed that 
de-escalation therapy was a protective factor not only for 
in-hospital but also for 90-day mortality. Interestingly, Leone 
et al’s24 multicenter nonblinded randomized noninferiority 
trial did not show a different mortality rate, but the strategy 
based on de-escalation of antibiotics resulted in prolonged 
duration of ICU stay.
General management paradigms
While different organizations agree that the topics of the indi-
vidual elements in the SSC care bundles – fluid resuscitation, 
hemodynamic management, and antibiotic administration – 
should be included in general management of severe sepsis 
and septic shock patients, they have suggested different 
approaches.
Fluid resuscitation
The effects of the use of aggressive fluid resuscitation and 
types of fluids in severe sepsis patients continue to be debated. 
Several studies have been published to determine the efficacy 
of crystalloids compared with that of colloids. Colloids are 
used as they are thought to remain in the intravascular space 
longer, achieve faster circulatory stabilization, and require less 
amount of fluid for resuscitation compared with crystalloids.25 
Table 2 Common delays in antibiotic administration in landmark 
sepsis studies
Author n Setting Median  
time (minutes)




261 eD, USA  
(shock)
119 0.30
(first hour vs  
all times)
Daniels62 567 whole Hospital, 
UK
121 0.62




2,154 eD, Canada  
(shock)
360 0.59




375 whole Hospital, 
UK
240 0.74
(first 3 hours  
vs delayed)
Levy et al64 15,022 Multicenter 0.86
(first 3 hours  
vs delayed)
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Perner et al26 elegantly demonstrated that patients with severe 
sepsis who received fluid resuscitation with HES 130/0.42 
had increased mortality, increased risk of renal replacement 
therapy, a tendency toward increased bleeding, and increased 
blood product transfusion when compared with resuscitation 
with Ringers acetate. Myburgh et al27 assigned 7,000 patients 
who had been admitted to an ICU in a 1:1 ratio to receive 
either 6% HES with a molecular weight of 130 kD and a molar 
substitution ratio of 0.4 (130/0.4, Voluven, Fresenius Kabi 
Norge AS, Halden, Norway) in 0.9% sodium chloride or 0.9% 
sodium chloride (saline) for all fluid resuscitation and found 
no difference in 90-day mortality in a heterogeneous group 
of critically ill patients. Therefore, taking into consideration 
the absence of significant clinical benefit and the potential 
harmful effect of starches based on the above studies, the 
2013 SSC28 guidelines recommended against using any 
HES in patients with severe sepsis. Three additional studies 
should be mentioned: SAFE trial,29 Therapy in the Colloids 
Versus Crystalloids for the Resuscitation of the Critically Ill 
(CRISTAL) trial,30 and albumin replacement in patients with 
severe sepsis or septic shock (ALBIOS).31 The SAFE trial 
compared the effect of fluid resuscitation with albumin or 
saline on mortality in a heterogeneous population of patients in 
the ICU in a multicenter, randomized, double-blind study and 
found that the use of either 4% albumin or normal saline for 
fluid resuscitation results in similar outcomes at 28 days. The 
CRISTAL trial tested whether the use of colloids compared 
with that of crystalloids for fluid resuscitation alters mortality 
in patients admitted to the ICU with hypovolemic shock and 
found that the use of colloids vs crystalloids did not result in a 
significant difference in 28-day mortality. On the other hand, 
in the ALBIOS trial, 1,818 patients from 100 ICUs with severe 
sepsis were randomly assigned to receive either 20% albumin 
and crystalloid solution or crystalloid solution alone. Authors 
found no mortality differences at 28 and 90 days. However, 
the post hoc univariate and multivariate analyses of data from 
the 1,121 patients with septic shock showed significantly 
lower mortality at 90 days in the albumin group than in the 
crystalloid group. Conversely, in the subgroup of patients with 
severe sepsis without shock, mortality appeared to be higher 
among those who were treated with albumin than among those 
treated with crystalloids alone.
Current hemodynamic 
management
Several recommendations have been made to optimize 
hemodynamic monitoring. Despite debate over the use of 
CVP levels as measures instead of dynamic parameters, 
the overriding goal is to achieve an optimal blood flow to 
the tissues. No large, randomized controlled trial exists to 
support a mean arterial pressure (MAP) target in sepsis. 
A higher MAP goal than the current 65 mmHg that was 
recommended by the SSC may theoretically improve end-
organ perfusion, especially for those with chronic hyperten-
sion. However, whether this blood pressure target is more 
or less effective than a higher target is unknown. For this 
reason, a multicenter, open-label trial (SEPSISPAM) was 
conducted, and 776 patients were assigned a target MAP of 
either 80–85 mmHg (high-target group) or 65–70 mmHg 
(low-target group).32 The authors found no difference in 
either 28-day mortality (36.6% vs 34% [HR, 1.07; 95% CI, 
0.84–1.38]) or 90-day mortality (43.8% vs 42.3% [RR, 1.04; 
95% CI, 0.83–1.30]). Interestingly, the authors found less use 
of renal support in chronic hypertensive patients (42.2% vs 
31.7% [OR 0.64; 95% CI, 0.41–0.99; P=0.046]). Some points 
should be mentioned regarding interpretation of the results 
of this study: It was not blinded; there was an incomplete 
recording of inclusion variables (right-heart catheterization, 
pulse pressure measurement, stroke volume measurement, 
and echocardiography); it was underpowered secondary to 
lower-than-expected mortality; MAPs achieved tended to be 
above their goal ranges (70–75 and 85–90 mmHg); there was 
widespread corticosteroid use; and the incidence of stroke 
was not measured, which is problematic given the rate of 
atrial fibrillation reported (2.8% vs 6.7% [P=0.02]).
Novel approaches in the pipeline
Mesenchymal stem cells
In sepsis, endothelial damage leads to further organ deterio-
ration. Despite the use of different experimental therapies 
to block the immune cascade, often damage has already 
occurred. The use of mesenchymal stem cells (MSCs) has 
been a promising alternative in a variety of diseases, includ-
ing cardiovascular, neurodegenerative, peripheral vascular, 
renal, and others. Their beneficial effects are due to the abil-
ity of MSC to repair tissue in injury and inflammation, to 
attenuate the inflammatory response, and to accelerate tissue 
healing and neoangiogenesis.33,34
The potential therapeutic value of cell-based therapy 
with MSC has been reported in mouse models of polymi-
crobial peritoneal sepsis. The potential therapeutic effect of 
intravenous bone marrow-derived human MSC in peritoneal 
sepsis induced by Gram-negative bacteria has been tested.35 
In this model, survival was significantly increased, and a 
marked reduction in the number of bacterial colony-forming 
units of Pseudomonas aeruginosa was shown in the blood 
treated with intravenous MSC compared with control mice. 
The effect was in part explained by a monocyte-dependent 





increase in bacterial phagocytosis. While this is a new area 
of investigation, several studies are being conducted, and the 
body of evidence is rising. It is important to take into account 
that sepsis is a complex process where several factors play 
key roles in the pathogenesis: direct effects of bacterial com-
pound, cytokine storm, activation of the endothelium, and 
subsequently the complement and coagulation process. By 
affecting the overall cascade, MSC would be helpful in restor-
ing and counteracting the deleterious effect that sepsis creates 
in the tissues. The encouraging trials in animal models would 
likely transfer to clinical settings, but a rational and careful 
approach with deep understanding of MSC mechanisms and 
actions is warranted under inflammatory conditions.
Blood purification
Therapies based on blood purification to counteract the del-
eterious effects of bacteria on the endothelium have recently 
emerged.36 The vast majority of the studies are focused on 
blocking endotoxin, one of the principal components on the 
outer membrane of Gram-negative bacteria, as it is consid-
ered to be a factor in sepsis pathogenesis. High levels of 
endotoxin activity have been associated with worse clinical 
outcomes.37 A landmark study was published in 2009.38 With 
a limited sample size (64 patients), polymyxin B hemoperfu-
sion added to conventional therapy significantly improved 
hemodynamics and organ dysfunction and reduced 28-day 
mortality in severe sepsis and septic shock patients affected 
by Gram-negative infections. In addition, a systematic review 
and meta-analysis of randomized trials were conducted to 
determine the association between various blood purification 
techniques and all-cause mortality in humans with sepsis.36 
A total of 16 trials (n=827) were analyzed, and blood purifica-
tion techniques including hemoperfusion, plasma exchange, 
and hemofiltration with hemoperfusion were associated with 
lower mortality in patients with sepsis. However, after pool-
ing all trials of blood purification for treatment of sepsis, the 
therapies were not associated with lower mortality.
At this writing, three studies of blood purification treat-
ments are being conducted. ABDO-MIX is a multicenter 
French Phase III study of hemoperfusion with a polymyxin 
column vs standard therapy in patients with peritonitis and 
septic shock. EUPHRATES is a multicenter US-based 
Phase III trial in patients with confirmed endotoxemia, 
incorporating sham perfusion and two treatments in 
24 hours with polymyxin. SAFE-BT is a randomized, multi-
center, controlled clinical study on the effect of the selective 
adsorption system for removal of negatively charged large 
biomolecules. The forthcoming results of these studies 
should provide a strong recommendation regarding the exact 
role, benefits, and cost-effectiveness of blood purification 
therapies.
Other therapies
Apart from the aforementioned therapies, there are some 
promising therapies to be considered in the future, two of 
which are of special relevance: innate immunity modula-
tion with the use of infused immunoglobulin (IgM enriched 
immunoglobulins) and antioxidative therapies.
The efficacy of polyclonal intravenous immunoglobu-
lin (IVIG) as adjunct therapy in sepsis has been a matter 
of debate over the last few years.39 Interestingly, several 
studies have shown a good correlation with low levels of 
certain immunoglobulins in blood in patients with severe 
sepsis. Tamayo et al40 described an inverse correlation of the 
levels of IgG1, IgG2, IgG3, IgM, IgA, and total IgG to the 
probability of death at 28 days. Recently, a meta-analysis that 
included 43 out of 88 potentially eligible studies found that 
there was a favorable outcome among adults with sepsis 
with the infusion of polyclonal IVIG but only with a very 
selected population.
During the sepsis injury and the inflammatory response, 
there is a marked oxidative state that may result in organ 
damage,41 for which the potential benefit of modulation by 
antioxidant therapy has been suggested. There is a molecule 
that seems to be promising in animal studies via antioxidant 
effects: melatonin. Fink et al42 recently discovered that 
melatonin receptors mediate improvements of survival 
after polymicrobial sepsis. While studies in patients are still 
being awaited, melatonin seems to be very promising for 
future RCT.
Updates on controversial topics
Tight glycemic control
Hyperglycemia is very common in patients with sepsis. 
At the same time, hyperglycemia has been reported to be 
associated with adverse events, including oxidative stress 
disorder, impairment of the immune system that might carry 
a higher susceptibility to infection due to an endothelial 
dysfunction.43 Several studies in the past found that the 
presence of hyperglycemia was independently associated 
with increased mortality in critically ill patients,44 especially 
in those with sepsis.45 Before the launch of the SSC 2013 
update, the previous guidelines included a recommendation 
for intensive insulin therapy (IIT). However, some RCTs that 
have attempted to determine whether IIT targeted toward 
establishing normoglycemia could benefit septic patients 
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have produced inconsistent results. A meta-analysis up to 
September 2013 that included randomized controlled trials 
of 4,100 patients comparing IIT with conventional glucose 
management in septic patients found that IIT did not reduce 
any of the outcomes: overall, 28-day, 90-day, ICU, and hos-
pital mortality.46 As secondary outcomes, neither severity of 
illness nor length of ICU stay was better in patients with IIT. 
On the contrary, the incidence of hypoglycemia was mark-
edly higher with the IIT. Therefore, the 2013 update of the 
SSC guidelines included a strong recommendation for a 
protocolized approach to blood glucose management in ICU 
patients with severe sepsis, commencing insulin dosing when 
two consecutive blood glucose levels are 180 mg/dL. This 
protocolized approach should target an upper blood glucose 
level 180 mg/dL rather than an upper target blood glucose 
level 110 mg/dL. The use of automated closed-loop control 
based on subcutaneous glucose measurements is currently 
feasible and may provide efficacious and hypoglycemia-free 
glucose control in critically ill adults.47
Corticosteroids: friend or foe
Endogenous glucocorticoids as end-effectors play a role 
in inhibiting inflammation, but are not always effective in 
suppressing the cytokine storm driven by a systemic inflam-
mation, even though cortisol levels have been correlated with 
grades of severity of illness and mortality. With the concept 
of corticosteroid illness-related corticosteroid insufficiency 
(CIRCI) and the results of clinical trials showing immune and 
hemodynamic benefits, corticosteroid therapy has re-emerged 
as a promising adjunct for the treatment of severe sepsis. 
From the 1950s to the 1980s, high-dose steroids were used 
in the management of sepsis. Over the last 40 years, the use 
of steroids for treatment of infections, sepsis, and septic 
shock has vacillated (Figure 2).14,48–57 While the use until the 
late 1990s was based mainly on high doses, the use of low 
doses (relative adrenal insufficiency dose) has since been 
the focus of study. On the basis of more recent evidence 
and published meta-analysis, the benefit of treatment with 
steroids seems to be limited to patients with vasopressor-
dependent septic shock with adequate fluid resuscitation. The 
adrenocorticotropic hormone stimulation test should not be 
used to identify those patients with septic shock who should 
receive glucocorticoids.
Diagnosis mandates: how to use 
biomarkers wisely
The use of biomarkers has been promising for sepsis man-
agement. Results from clinical trials of biomarker-guided 
therapeutic drugs that boost immunity showed promising 
findings in sepsis.58 Whereas the use of such markers has 
been focused on the diagnosis of sepsis, in order to dif-
ferentiate between infectious and noninfectious processes, 
new developments are based on monitoring the response to 
the treatment in patients with sepsis. Several biomarkers 
have been proposed, but it is important to note the use of 
procalcitonin for targeting treatment duration, and resolu-
tion of sepsis. Procalcitonin has also been found useful to 
implement an appropriate plan of treatment, to measure and 
tailor the response of the treatment and a good correlation 
with clinical severity. In addition, biomarker guidance of 
antibiotic stewardship seems to be a very promising new 
approach. In several randomized controlled trials, including 
Figure 2 Steroids for treatment of infections, sepsis, and septic shock – ups and downs.
Abbreviations: SSC, Surviving Sepsis Campaign.





critically ill adult patients, procalcitonin guidance was repeat-
edly associated with a decrease in the duration of antibiotic 
therapy.59
Probably because the sepsis process has a very complex 
pathophysiology, many biomarkers have been considered. 
Many markers are based on inflammation monitoring, but 
coagulation, complement, contact system activation, and 
apoptosis have been proposed to play a fundamental role.60 
Therefore, several markers might be used to inform about 
which part of the system is affected.
Final considerations
The appropriate balance between inflammation and anti-
inflammation seems to be fundamental to a better under-
standing of the sepsis syndrome. Several mediator-selective 
anti-inflammatory drugs were utilized for a brief period, 
but were considered disappointing. While an exaggerated 
inflammatory response is deleterious, the timing and appro-
priateness of therapy may be key to patient outcomes. To 
date, more than 100 RCTs (Phases I–III) looking at therapies 
that can modulate inflammation have been conducted, with 
contradictory results. With more than 200 potential targets, it 
is worrisome that there are no definitive therapies to improve 
the outcome in septic patients.
Additional considerations should be taken into account. 
First, sepsis is a complex process with a high degree of 
heterogeneity. One patient will not modulate the infectious 
insult and the inflammatory response in the same manner as 
another. Second, therapeutic interventions are often not given 
in an appropriate dosage or duration. In addition, the timing 
of interventions affects therapeutic modulation, so time of 
diagnosis is crucial. The outcome of the patient is a matter 
of debate. Also, different endpoints have been considered 
(ie, ICU, 28-day, 90-day, hospital mortality, etc), but other 
less rigid surrogates such as length of stay or ventilator-free 
days are being included as the primary outcome of the RCT. 
In addition, quality of life after discharge is a cornerstone 
and might provide the balance in the investment for health 
care system sustainability.
Summary
An urgent need exists for correct patient classification that 
describes the degree of immune response.60 Monitoring 
immune status with the use of panels of biomarkers at regular 
intervals to assess the clinical and immune response seems to 
be a rational approach to better understand the value of the 
treatments provided. Much larger sample sizes will be needed 
to detect the relatively smaller effects of new therapies for 
sepsis. Further, revising the definition of sepsis to be sure that 
RCTs recruit appropriate patients remains a challenge.
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